U.S. Physical Therapy enters the week after its most punishing earnings reaction in recent memory — a 19.5% single-day collapse following Q1 results on May 7 — with the stock now trading at $60.85, down 20% over the past month and nearly 30% off its year-to-date range. That gap between where the stock is and where analysts think it should be is the defining tension right now.
The earnings miss was jarring on the surface but nuanced underneath. Q1 revenue came in at $198 million — up 7.9% year-on-year — but net income fell sharply to $5 million against $9.9 million a year earlier. Basic EPS from continuing operations swung to a $0.12 loss versus $0.80 profit. On the call, CEO Christopher Reading reaffirmed full-year guidance and pointed to weather disruptions costing over 31,000 visits in the quarter, plus front-desk virtualisation and ambient AI documentation initiatives expected to improve margins as the year progresses. The market was not persuaded. The stock fell nearly 18% the day before the formal print, implying some information was already circulating, and then lost another leg on the earnings day itself.
The most telling shift this week is in options, not short interest. The put/call ratio collapsed from near its 52-week high — it ran above 4.9 for most of late April and early May — to 1.21 on May 12. That is more than 1.3 standard deviations below its 20-day average of 3.47, a dramatic unwind of defensive positioning. For weeks the options market was priced for a bad outcome; following the sell-off, that downside protection has been largely unwound. Whether that reflects relief or capitulation is the open question. Short interest, by contrast, has drifted modestly higher over the week — rising roughly 4.5% to around 6.7% of the free float — after pulling back from a local peak above 7.1% in mid-April. That modest rebuild suggests some fresh bearish conviction, but the level remains well below the March 13 spike of 8.1% that briefly appeared in the data. Borrow conditions are not signalling a squeeze: cost-to-borrow has actually eased this week to 0.49% and borrow availability remains loose, far from the tight conditions that would constrain further shorting.
The Street has moved fast to reset expectations. Barrington Research trimmed its target from $103 to $90 this morning while keeping an Outperform rating. Citizens, earlier in the week, cut from $113 to $98, also maintaining its positive stance. That leaves the consensus price target at roughly $97 — a 58% premium to the current price. Jefferies, which initiated with a Buy and $102 target in March, has not been heard from since the print. Taken together, coverage remains constructive but is clearly ratcheting back its near-term confidence. The bull case — reiterated as recently as May 10 — centres on the NYU and Gulf Coast hospital partnerships now actively ramping, potential Medicaid rate improvement, and a valuation that has compressed to around 10.7x 2026 EBITDA, well below the stock's historical average closer to 15x. The bear case is structural: EPS momentum is deeply negative (ranked in the 21st percentile on a 30-day basis), earnings surprise history sits at the 8th percentile, and two consecutive quarters of net-income decline despite solid revenue growth suggest the cost structure remains problematic. EV/EBITDA has crept up slightly on the week as the enterprise value adjusted to the lower equity price, now running at 13.9x.
Institutional ownership data, current through April 30, shows BlackRock adding modestly to a 14.5% stake and Bahl & Gaynor increasing by over 184,000 shares as of March 31 — both pre-print moves that now sit underwater. Copeland Capital and Schroder also added meaningful positions in Q1. None of these are distressed sellers by nature, but the speed of the drawdown means mark-to-market pressure across the holder base is real. Insider activity through March was entirely one-directional: the COO, General Counsel, and President/COO all sold between late February and mid-March at prices ranging from $78 to $86 — all above the current $60.85 level. The pattern is worth noting, though the sizes were modest and the trades predate the Q1 release.
The next focal point is whether the stock can stabilise long enough for the operational progress outlined on the May 7 call — NYU clinic transitions, front-desk virtualisation savings, and the cash-based programme rollout across major partnerships — to show up in Q2 numbers. The dividend history in the data appears to be stale (last confirmed entry from May 2022), so income-oriented buyers should verify current payout status before drawing conclusions. With no confirmed next earnings date yet announced and short interest sitting at a quietly elevated but not extreme 6.7% of float, the stock is in a period where the narrative is ahead of the numbers.
See the live data behind this article on ORTEX.
Open USPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
